Please wait a minute...
文章检索
预防医学  2024, Vol. 36 Issue (1): 55-57    DOI: 10.19485/j.cnki.issn2096-5087.2024.01.014
  疾病控制 本期目录 | 过刊浏览 | 高级检索 |
海曙区水痘突破病例特征分析
李保军1, 施方伦2, 林伊荷1, 童思未1, 刘芳3
1.海曙区疾病预防控制中心疾病控制科,浙江 宁波 315012;
2.海曙区古林镇卫生院,浙江 宁波 315099;
3.宁波大学附属第一医院,浙江 宁波 315010
Characteristics of varicella breakthrough cases in Haishu District
LI Baojun1, SHI Fanglun2, LIN Yihe1, TONG Siwei1, LIU Fang3
1. Department of Infectious Disease Control, Haishu District Center for Disease Control and Prevention, Ningbo, Zhejiang 315012, China;
2. Gulin Health Center, Ningbo, Zhejiang 315099, China;
3. The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China
全文: PDF(820 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2017—2022年浙江省宁波市海曙区水痘突破病例特征,为预防水痘疫情提供依据。方法 通过中国传染病报告管理信息系统和浙江省免疫规划信息系统,收集2017—2022年海曙区水痘报告病例资料和疫苗接种信息;发病前42 d接种过1剂次或2剂次水痘疫苗定义为突破病例,分析其性别、年龄、地区及发病与末次免疫间隔时间分布特征。结果 2017—2022年海曙区报告水痘病例1 563例,突破病例928例,占总病例的59.37%。1剂次免疫史突破病例660例,占总病例的42.23%;2剂次免疫史突破病例268例,占总病例的17.15%。2017—2022年1剂次免疫史突破病例占当年水痘病例的比例呈下降趋势(P<0.05);2剂次免疫史突破病例占当年水痘病例的比例无明显变化趋势(P>0.05)。1剂次免疫史突破病例男性392例,占59.39%;女性268例,占40.61%。2剂次免疫史突破病例男性150例,占55.97%;女性118例,占44.03%。1、2剂次免疫史突破病例年龄MQR)分别为13.00(4.00)岁和9.00(4.00)岁,差异有统计学意义(P<0.05)。1、2剂次免疫史突破病例地区分布均以城乡接合部为主,分别为319例(48.33%)和137例(51.12%),差异有统计学意义(P<0.05)。1、2剂次免疫史突破病例发病与末次免疫间隔时间MQR)分别为12.00(3.00)年和4.00(3.00)年,差异有统计学意义(P<0.05)。结论 2017—2022年海曙区水痘突破病例以1剂次免疫史突破病例、男性、城乡接合部居民为主,1剂次免疫史突破病例年龄、发病与末次免疫间隔时间大于2剂次免疫史突破病例。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
李保军
施方伦
林伊荷
童思未
刘芳
关键词 水痘突破病例疫苗接种    
AbstractObjective To investigate the characteristics of breakthrough cases of varicella in Haishu District, Ningbo City, Zhejiang Province from 2017 to 2022, so as to provide the evidence for varicella prevention and control. Methods Information on reported cases of varicella and vaccination in Haishu District from 2017 to 2022 were collected through the China Infectious Disease Reporting Management Information System and the Immunization Program Information Management System of Zhejiang Province. The breakthrough cases who had received 1 or 2 doses of varicella vaccine 42 days before the onset of disease were selected. The distribution of sex, age, region and the interval between onset and last immunization were descriptively analyzed. Results A total of 1 563 varicella cases were reported from 2017 to 2022. There were 928 breakthrough cases (59.37%), of which 660 cases with 1-dose immunization history (42.23%) and 268 cases with 2-dose immunization history (17.15%). The proportion of 1-dose breakthrough cases in total annual cases showed a decreasing trend (P<0.05) from 2017 to 2022, while there was no significant tendency on the proportion of cases with 2-dose immunization history (P>0.05). There were 392 males (59.39%) and 268 females (40.61%) with 1-dose immunization history. There were 150 males (55.97%) and 118 females (44.03%) with 2-dose immunization history. Breakthrough cases with 1- and 2- dose immunization history had an median age of 13.00 (interquartile range, 4.00) and 9.00 (4.00) years, respectively, and the difference was statistically significant (P<0.05). The regional distribution of the breakthrough cases with 1- and 2- dose immunization history was mainly in the rural-urban fringe, with 319 cases (48.33%) and 137 cases (51.12%), respectively, and the difference was statistically significant (P<0.05). The median interval between onset and last immunization was 12.00 (interquartile range, 3.00) and 4.00 (3.00) years, respectively, and the difference was statistically significant (P<0.05). Conclusions The breakthrough cases of varicella in Haishu District from 2017 to 2022 were mainly cases with 1-dose immunization history, males, and residents in rural-urban fringe. The age was older and the interval between onset and the last immunization was longer in cases with 1-dose immunization history than in cases with 2-dose immunization history.
Key wordsvaricella    breakthrough case    vaccination
收稿日期: 2023-09-15      修回日期: 2023-10-30      出版日期: 2024-01-10
中图分类号:  R181.3  
基金资助:长三角免疫规划领军人才科研项目(CSJP024)
作者简介: 李保军,本科,副主任医师,主要从事传染病防控和免疫规划工作
通信作者: 童思未,E-mail:tsw-1977@163.com   
引用本文:   
李保军, 施方伦, 林伊荷, 童思未, 刘芳. 海曙区水痘突破病例特征分析[J]. 预防医学, 2024, 36(1): 55-57.
LI Baojun, SHI Fanglun, LIN Yihe, TONG Siwei, LIU Fang. Characteristics of varicella breakthrough cases in Haishu District. Preventive Medicine, 2024, 36(1): 55-57.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2024.01.014      或      http://www.zjyfyxzz.com/CN/Y2024/V36/I1/55
[1] 何飞,马永法,顾春艳,等.2005—2021年盐都区水痘流行特征[J].预防医学,2023,35(1):61-64.
[2] 张军楠,黄卓英,王淼,等.中国水痘减毒活疫苗的安全性、免疫原性和保护效果[J].中国疫苗和免疫,2018,24(4):487-491.
[3] 许小康,孟祥梅,王瑶,等.六安市某小学水痘暴发疫情突破病例分析[J].预防医学,2020,32(3):289-291.
[4] 黄恩妙,王翠玲,吕海英.中山市1起小学水痘暴发疫情调查[J].预防医学,2021,33(4):391-394.
[5] 随海田,李锦成,王淼,等.2005—2015年中国水痘流行病学特征[J].中国疫苗和免疫,2019,25(2):155-159.
[6] 董蒲梅,王淼,刘燕敏.2016—2019年中国水痘流行病学特征[J].中国疫苗和免疫,2020,26(4):403-406.
[7] 李寿俊,夏颖苹,董维波,等.2013—2016年浙江省宁波市奉化区水痘流行特征分析[J].疾病监测,2018,33(8):649-652.
[8] 张磊,刘元宝,孙翔,等.2017年江苏省32起水痘暴发流行病学特征及突破病例分析[J].中华疾病控制杂志,2018,22(9):975-977.
[9] 朱丽霞,刘玉梅,周光华,等.重庆市北碚区0~6岁儿童水痘及突破病例流行特征[J].热带医学杂志,2019,19(1):99-102.
[10] 潘兴强,马瑞,方挺,等.宁波市2010—2014年水痘暴发疫情及其突破病例分析[J].中国预防医学杂志,2016,17(7):514-517.
[11] 师燕,朱一凡,王静,等.长垣市儿童接种不同剂次水痘疫苗免疫史突破病例分析[J].黑龙江医学,2022,46(17):2104-2016.
[12] 陈颖萍,邓璇,何寒青,等.浙江省水痘暴发疫情流行特征分析[J].预防医学,2020,32(4):366-368,372.
[13] 蒋静凤,王旭雯.无锡2017—2018年儿童水痘疫情中突破性病例分析[J].中国学校卫生,2020,41(8):1253-1255.
[1] 王瑶, 潘璠, 张欢, 陈亚飞, 秦伟. 气温对六安市水痘发病风险的影响研究[J]. 预防医学, 2023, 35(8): 692-696.
[2] 陈劲华, 楼灵巧, 陶静波, 万斌斌, 成航, 贾建伟, 骆淑英. 义乌市百日咳病例流行病学特征分析[J]. 预防医学, 2023, 35(11): 981-984.
[3] 何飞, 马永法, 顾春艳, 潘铭, 陈万庚. 2005—2021年盐都区水痘流行特征[J]. 预防医学, 2023, 35(1): 61-64.
[4] 陈蓓蕾, 王瑶, 陈智超, 潘璠, 解少煜, 秦伟. 六安市1~12岁儿童水痘-带状疱疹病毒抗体水平调查[J]. 预防医学, 2022, 34(5): 503-506.
[5] 吴晨, 吴昊澄, 鲁琴宝, 丁哲渊, 王心怡, 傅天颖, 杨珂, 林君芬. 浙江省境外输入新型冠状病毒肺炎病例流行特征[J]. 预防医学, 2022, 34(12): 1245-1250.
[6] 高波, 薛琦臻, 张俊锋, 潘冉冉, 孙烨祥. 2010—2020年鄞州区水痘流行特征分析[J]. 预防医学, 2021, 33(9): 913-915.
[7] 卢肇骏, 沈鹏, 孙烨祥, 潘兴强, 杨颖, 王炜豪, 郑卫军. 鄞州区2009—2018年出生儿童水痘疫苗接种保护效果分析[J]. 预防医学, 2021, 33(8): 804-807.
[8] 沈建勇, 张超, 罗小福, 徐秦儿, 陈奕晔. 湖州市1~12岁儿童水痘疫苗接种情况调查[J]. 预防医学, 2021, 33(6): 624-626.
[9] 黄恩妙, 王翠玲, 吕海英. 中山市1起小学水痘暴发疫情调查[J]. 预防医学, 2021, 33(4): 391-394.
[10] 田红霞, 任重, 刘兰, 黄荷丽. 2005—2019年株洲市百日咳流行特征分析[J]. 预防医学, 2021, 33(4): 395-397,403.
[11] 许玉洋, 刘艳, 张小平, 杜渐, 车鑫仁, 王骏, 顾雯雯, 张学潮, 江伟. 杭州市2~11岁儿童水痘减毒活疫苗接种情况调查[J]. 预防医学, 2020, 32(7): 689-691.
[12] 陈颖萍, 邓璇, 何寒青, 王慎玉, 梁贞贞, 胡晓松, 邢博, 吕华坤. 浙江省水痘暴发疫情流行特征分析[J]. 预防医学, 2020, 32(4): 366-369.
[13] 许小康, 孟祥梅, 王瑶, 解少煜, 龚鹏飞, 夏峰, 秦伟. 六安市某小学水痘暴发疫情突破病例分析[J]. 预防医学, 2020, 32(3): 289-291.
[14] 朱珠英, 周珊慧. 龙湾区健康人群水痘-带状疱疹病毒抗体水平调查[J]. 预防医学, 2020, 32(11): 1144-1146.
[15] 魏晶娇, 倪朝荣, 邵永强, 李万仓, 王志刚, 孙肖瑜, 刘可欣, 杨海燕. 2010—2018年温州市水痘流行特征分析[J]. 预防医学, 2020, 32(11): 1141-1143.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed